Jin Ye, Liang Zhi-Yong, Zhou Wei-Xun, Zhou Li
a Clinical Research Laboratory, Peking Union Medical College Hospital , Chinese Academy of Medical Sciences/Peking Union Medical College , Beijing 100730 , China.
b Department of Pathology, Peking Union Medical College Hospital , Chinese Academy of Medical Sciences/Peking Union Medical College , Beijing 100730 , China.
J Invest Surg. 2018 Oct;31(5):412-419. doi: 10.1080/08941939.2017.1347218. Epub 2017 Jul 31.
Hepatocyte Paraffin 1 (Hep Par 1) and cytokeratin 19 (CK19) were shown to be associated with post-surgical prognosis of hepatocellular carcinoma (HCC). However, further validation might be needed. Besides, their combined evaluation has not been reported. The present study was designed to address the issues.
Expressions of Hep Par 1 and CK19 were detected using tissue microarray-based immunohistochemical staining in 79 patients with HCC underwent curative hepatectomy. Their associations with cliniopathologic variables, overall and recurrence-free survival were analyzed.
Hep Par 1 was highly expressed in 61 patients (77.2%), whereas CK19 was positive in 8 patients (10.1%). Moreover, expressions of these two proteins were all associated with tumor-node-metastasis (TNM) stage and vascular invasion. It was found that high Hep Par 1 expression was univariately associated with good overall and recurrence-free survival, while CK19 was marginally prognostic. Also in univariate analyses, combination of the two markers more effectively predicted for long-term prognosis in HCC than Hep Par 1 did. However, neither Hep Par 1 nor Hep Par 1/CK19 was multivariately significant. Finally, Hep Par 1/CK19 combined with TNM stage might obtain more satisfactory outcome prediction, especially for overall survival.
Combination of CK19 with Hep Par 1 might have higher prognostic power, which might be further improved by adding TNM stage, than Hep Par 1 alone, in resected HCC. Of course, subsequent confirmation is necessary.
肝细胞石蜡1(Hep Par 1)和细胞角蛋白19(CK19)已被证明与肝细胞癌(HCC)的术后预后相关。然而,可能需要进一步验证。此外,它们的联合评估尚未见报道。本研究旨在解决这些问题。
采用基于组织芯片的免疫组化染色法检测79例行根治性肝切除术的HCC患者中Hep Par 1和CK19的表达。分析它们与临床病理变量、总生存期和无复发生存期的关系。
61例患者(77.2%)Hep Par 1高表达,而8例患者(10.1%)CK19呈阳性。此外,这两种蛋白的表达均与肿瘤-淋巴结-转移(TNM)分期和血管侵犯相关。发现Hep Par 1高表达单因素分析与良好的总生存期和无复发生存期相关,而CK19的预后价值较小。在单因素分析中,两种标志物联合比Hep Par 1更有效地预测HCC的长期预后。然而,Hep Par 1和Hep Par 1/CK19在多因素分析中均无显著意义。最后,Hep Par 1/CK19联合TNM分期可能获得更满意的预后预测,尤其是总生存期。
在切除性HCC中,CK19与Hep Par 1联合可能比单独的Hep Par 1具有更高的预后价值,通过增加TNM分期可能进一步提高预后价值。当然,后续的验证是必要的。